封面
市場調查報告書
商品編碼
2162593

兒童免疫疫苗市場:全球市場預測,2026-2032年

Pediatric Preventable Vaccine Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,兒童免疫疫苗市場規模將成長至 15.9129 億美元,複合年成長率為 10.21%。

主要市場統計數據
基準年 2025 8.0548億美元
預計年份:2026年 8.8865億美元
預測年份 2032 1,591,290,000 美元
複合年成長率 (%) 10.21%

兒童預防性疫苗:執行摘要

兒童免疫接種是預防可能導致兒童嚴重、殘疾甚至死亡的感染疾病的基礎。其公共衛生價值不僅限於個人接種,還能控制感染傳播,保護那些無法接種疫苗的族群,並減輕醫療系統的負擔。這些計畫的成功取決於穩定的疫苗供應、基於實證醫學的接種計劃、訓練有素的醫護人員、知情的家長以及公眾的持續信任。

供應鏈正在朝著優先考慮韌性和公平性的方向轉變。

透過加強常規免疫接種、彌補漏種疫苗以及改善服務不足人口的接種途徑,現狀正在改變。衛生部門更重視綜合基層醫療、校內免疫接種、社區外展服務、冷鏈可靠性以及及時的疾病監測。由於衝突、流離失所、地理因素、收入和服務中斷等因素可能導致兒童免疫接種率持續存在差距,因此公平性問題變得日益重要。

人工智慧(AI)可以改善規劃、推廣和監測。

人工智慧 (AI) 可以透過識別疫苗接種率低的風險地區、協助需求預測、最佳化疫苗接種路線以及支持醫護人員的記錄工作,為兒童免疫接種計劃做出貢獻。它還有助於與家長進行多語言溝通,並檢測安全和疾病監測系統中的異常情況。有效利用人工智慧需要高品質的資料、隱私保護、臨床監督、透明的檢驗以及防止輸出偏差的控制措施。人工智慧應該作為公共衛生決策的補充,而不是取代它們。

區域性見解:疫苗接種率的差異需要根據當地情況制定相應的方案。

北美地區普遍受益於完善的免疫基礎設施,但仍需解決接種障礙、錯誤資訊以及各轄區之間的差異。拉丁美洲的重點仍然是恢復常規服務,並涵蓋流動人口、偏遠地區和社會邊緣化群體。歐洲擁有成熟的醫療衛生體系,但也面臨疫苗接種猶豫、人口流動和疫苗接種率不均等挑戰。中東和非洲需要建立具有韌性的供應鏈、行動服務、疫情應對機制,並採取適當措施應對受衝突影響的弱勢群體。亞太地區的醫療衛生體系高度多元化,因此,最後一公里配送、都市區公平以及健全的監測體系尤其重要。

群體特定洞察:經濟和安全集團結成聯盟

東南亞國協需要協調跨境監測,並解決成員國間供給能力差異的問題。金磚國家成員國人口組成和醫療衛生體系各不相同,它們在保持各自國家優先事項的同時,正在創造在生產製造、採購和專案知識共用方面開展合作的機會。歐盟受益於協調的公共衛生機制以及國家層級的實施。七國集團成員國可以支持證據收集、資金籌措和全球免疫夥伴關係。海灣合作理事會成員國通常擁有健全的臨床基礎設施,但仍需持續支持流動人口和弱勢群體。北約成員國必須考慮在緊急情況、疏散和基本服務中斷期間,如何保障兒童免疫接種的連續性。

各國狀況分析:各國優先事項反映了不同的實施。

澳洲和加拿大必須在分散的社區中維持高疫苗接種率,同時解決影響原住民和偏遠地區人口的接種機會不平等。與巴西、墨西哥、印度和印尼合作的區域網路需要持續在龐大且多元化的人群中推廣,並關注疫苗接種的缺失情況和當地的服務能力。中國、日本和韓國除了致力於完善醫療衛生系統外,還在努力解決諸如提高免疫接種計劃的依從性、建立信任、應對人口結構變化等優先事項。法國、德國、義大利、西班牙和英國繼續將常規免疫接種率、家長信任和社區公平接種機會作為優先事項。俄羅斯面臨在其地域遼闊的系統中維持連續性和監測工作的挑戰。在這些國家,可靠的記錄、透明的溝通和對疫苗接種差異的快速反應仍然是通用的優先事項。

領導者的首要任務:建立信任、韌性和可衡量的成就。

產業和公共衛生領導者應提升端到端供應鏈的透明度,實現關鍵投入的多元化,並為偏遠和受干擾的環境設計交付模式。計畫應利用可互通的免疫接種記錄來識別疫苗接種不足的人群,並在必要時將診所與學校、藥房和社區服務機構連接起來。家長參與應根據當地情況量身定做,公開透明地說明益處和風險,並由值得信賴的醫療保健專業人員提供支援。領導者應建立公平性指標,監測不同族群的疫苗接種率和脫落率,使用代表性數據檢驗人工智慧工具,並確保所有營運和臨床決策都由人課責。

調查方法:基於證據的項目和政策指南整合

本執行摘要對與既定公共衛生原則、免疫規劃實踐、疾病監測考慮以及可預防兒童疫苗相關的區域實施情況進行了結構化、綜合性的定性分析。研究結果按地理區域、經濟和安全組別以及指定國家/地區進行分類。這種方法強調檢驗的規劃因素,例如常規服務的連續性、可近性、供應鏈韌性、看護者信心、監測和數位化管治。市場估計和預測、市場規模、市場佔有率、預測以及公司特定聲明均未納入本摘要。

結論:疫苗接種的持續有效性取決於系統的健全程度。

兒童可預防疫苗接種計畫要達到最佳效果,需要確保定期服務能可靠地維持,及時發現漏種情況,並贏得社區的信任。由於地區和國家之間存在差異,單一模式不足以應對所有情況,需要採取靈活的實施方案。結合穩健的後勤保障、公平的接種機會、完善的監測體系、負責任的數位化工具以及課責的領導,相關人員能夠提高接種工作的連續性,並為保護兒童免受可預防疾病的侵害做出貢獻。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章:兒童免疫疫苗市場:依疫苗類型分類

  • 白喉、破傷風、百日咳
  • B型流感嗜血桿菌
  • B型肝炎
  • 麻疹、腮腺炎、德國德國麻疹
  • 肺炎鏈球菌結合疫苗
  • 脊髓灰質炎
  • 水痘

第8章:兒童免疫疫苗市場:依年齡層別分類

  • 青春期
  • 嬰兒
  • 新生
  • 學前班
  • 學齡
  • 嬰兒

第9章:兒童免疫疫苗市場:依技術分類

  • 組合型
  • 失活
  • 減毒活病毒疫苗
  • 次單元
  • 類毒素

第10章:兒童免疫疫苗市場:依給藥途徑分類

  • 注射
  • 鼻腔
  • 口服

第11章:兒童免疫疫苗市場:以劑型分類

  • 多劑量
  • 單一劑量

第12章:兒童免疫疫苗市場:依通路分類

  • 私部門
    • 醫院藥房
    • 零售藥房
  • 公部門
    • 政府項目
    • 國際援助

第13章:兒童免疫疫苗市場:依最終用戶分類

  • 診所
    • 社區健康診所
    • 私人診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 推廣中心
    • 社區營地
    • 行動診所

第14章:兒童免疫疫苗市場:依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章:兒童免疫疫苗市場:依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章:兒童免疫疫苗市場:依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第18章:公司簡介

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • CSL Limited
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Moderna Inc.
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm Group Co. Ltd.
  • Sinovac Biotech Ltd.

第19章:關鍵專家

Product Code: MRR-710707546E77

The Pediatric Preventable Vaccine Market is projected to grow by USD 1,591.29 million at a CAGR of 10.21% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 805.48 million
Estimated Year [2026] USD 888.65 million
Forecast Year [2032] USD 1,591.29 million
CAGR (%) 10.21%

Pediatric Preventable Vaccines: Executive Summary

Pediatric preventable vaccines support protection against infectious diseases that can cause severe illness, disability, or death in children. Their public-health value extends beyond individual immunization by reducing transmission, protecting people who cannot be vaccinated, and limiting pressure on health systems. Program performance depends on reliable supply, evidence-based schedules, trained providers, informed caregivers, and sustained public confidence.

Delivery Systems Are Shifting Toward Resilience and Equity

The landscape is being reshaped by efforts to strengthen routine immunization, recover missed doses, and improve access for underserved populations. Health authorities are placing greater emphasis on integrated primary care, school-based delivery, community outreach, cold-chain reliability, and timely disease surveillance. Equity considerations are increasingly central because conflict, displacement, geography, income, and service interruptions can create persistent gaps in pediatric coverage.

Artificial Intelligence Can Improve Planning, Outreach, and Surveillance

Artificial intelligence can contribute to pediatric vaccination programs by identifying areas at risk of under-immunization, supporting demand forecasting, optimizing delivery routes, and helping health workers manage records. It may also assist with multilingual caregiver communications and signal detection in safety or disease-monitoring systems. Effective use requires high-quality data, privacy safeguards, clinical oversight, transparent validation, and controls against biased outputs; AI should augment, not replace, public-health judgment.

Regional Insights: Uneven Coverage Requires Locally Adapted Programs

North America generally benefits from established immunization infrastructure but must address access barriers, misinformation, and differences across jurisdictions. Latin America continues to focus on restoring routine services and reaching mobile, remote, and marginalized communities. Europe combines mature health systems with challenges linked to hesitancy, migration, and uneven uptake. The Middle East and Africa require resilient supply chains, mobile services, outbreak response, and approaches suited to conflict-affected and hard-to-reach populations. Asia-Pacific spans highly varied systems, making last-mile delivery, urban-rural equity, and strong surveillance particularly important.

Group Insights: Economic and Security Blocs Shape Coordination

ASEAN countries face the need to coordinate cross-border surveillance and address varied delivery capacity across member states. BRICS members represent diverse demographic and health-system conditions, creating opportunities for cooperation on manufacturing, procurement, and program learning while retaining distinct national priorities. The European Union benefits from coordinated public-health mechanisms alongside national implementation. G7 members can support evidence generation, financing, and global immunization partnerships. GCC countries generally have strong clinical infrastructure but still need consistent outreach for mobile and vulnerable populations. NATO members must consider continuity of pediatric immunization during emergencies, displacement, and disruptions to essential services.

Country Insights: National Priorities Reflect Different Delivery Contexts

Australia and Canada must maintain high coverage across dispersed communities and address access differences affecting Indigenous and remote populations. Brazil, Mexico, India, and Indonesia-linked regional networks require sustained outreach across large and diverse populations, with attention to missed children and local service capacity. China, Japan, and South Korea combine substantial health-system capability with priorities around schedule adherence, confidence, and demographic change. France, Germany, Italy, Spain, and the United Kingdom continue to emphasize routine coverage, caregiver trust, and equitable access across communities. Russia faces the importance of maintaining continuity and surveillance across a geographically extensive system. Across these countries, reliable records, transparent communication, and rapid response to coverage gaps remain common priorities.

Priorities for Leaders: Build Trust, Resilience, and Measurable Reach

Industry and public-health leaders should strengthen end-to-end supply visibility, diversify critical inputs, and design delivery models for remote and disrupted settings. Programs should use interoperable immunization records, identify missed-dose cohorts, and combine clinics with schools, pharmacies where appropriate, and community services. Engagement with caregivers should be locally tailored, transparent about benefits and risks, and supported by trusted health professionals. Leaders should establish equity metrics, monitor coverage and dropout rates by population group, test AI tools against representative data, and maintain human accountability for every operational and clinical decision.

Methodology: Evidence-Based Synthesis of Program and Policy Signals

This executive summary uses a structured qualitative synthesis of established public-health principles, immunization-program practices, disease-surveillance considerations, and regional delivery conditions relevant to pediatric preventable vaccines. Findings are organized across geographic regions, economic and security groups, and the specified countries. The approach emphasizes verifiable program factors such as routine-service continuity, access, supply-chain resilience, caregiver confidence, surveillance, and digital governance. It deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific claims.

Conclusion: Sustained Immunization Performance Depends on System Strength

Pediatric preventable vaccine programs deliver the greatest protection when routine services remain dependable, missed children are rapidly identified, and communities trust the information they receive. Regional and national differences require adaptable delivery rather than a single model. By combining resilient logistics, equitable access, strong surveillance, responsible digital tools, and accountable leadership, stakeholders can improve continuity and help protect children from preventable disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pediatric Preventable Vaccine Market, by Vaccine Type

  • 7.1. Introduction
  • 7.2. Diphtheria Tetanus Pertussis
  • 7.3. Haemophilus Influenzae Type B
  • 7.4. Hepatitis B
  • 7.5. Measles Mumps Rubella
  • 7.6. Pneumococcal Conjugate
  • 7.7. Polio
  • 7.8. Varicella

8. Pediatric Preventable Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adolescence
  • 8.3. Infant
  • 8.4. Neonate
  • 8.5. Preschool
  • 8.6. School Age
  • 8.7. Toddler

9. Pediatric Preventable Vaccine Market, by Technology

  • 9.1. Introduction
  • 9.2. Conjugate
  • 9.3. Inactivated
  • 9.4. Live Attenuated
  • 9.5. Subunit
  • 9.6. Toxoid

10. Pediatric Preventable Vaccine Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Injection
  • 10.3. Nasal
  • 10.4. Oral

11. Pediatric Preventable Vaccine Market, by Dosage Form

  • 11.1. Introduction
  • 11.2. Multi Dose
  • 11.3. Single Dose

12. Pediatric Preventable Vaccine Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Private Sector
    • 12.2.1. Hospital Pharmacies
    • 12.2.2. Retail Pharmacies
  • 12.3. Public Sector
    • 12.3.1. Government Programs
    • 12.3.2. International Aid

13. Pediatric Preventable Vaccine Market, by End User

  • 13.1. Introduction
  • 13.2. Clinics
    • 13.2.1. Community Health Clinics
    • 13.2.2. Private Clinics
  • 13.3. Hospitals
    • 13.3.1. Private Hospitals
    • 13.3.2. Public Hospitals
  • 13.4. Outreach Centers
    • 13.4.1. Community Camps
    • 13.4.2. Mobile Clinics

14. Pediatric Preventable Vaccine Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Europe
  • 14.6. Middle East
  • 14.7. Africa

15. Pediatric Preventable Vaccine Market, by Group

  • 15.1. Introduction
  • 15.2. ASEAN
  • 15.3. GCC
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. G7
  • 15.7. NATO

16. Pediatric Preventable Vaccine Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. United Kingdom
  • 16.7. Germany
  • 16.8. France
  • 16.9. Russia
  • 16.10. Italy
  • 16.11. Spain
  • 16.12. China
  • 16.13. India
  • 16.14. Japan
  • 16.15. Australia
  • 16.16. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AstraZeneca plc
  • 18.2. Bharat Biotech International Limited
  • 18.3. CSL Limited
  • 18.4. GlaxoSmithKline plc
  • 18.5. Johnson & Johnson
  • 18.6. Merck & Co. Inc.
  • 18.7. Moderna Inc.
  • 18.8. Novavax Inc.
  • 18.9. Pfizer Inc.
  • 18.10. Sanofi S.A.
  • 18.11. Seqirus
  • 18.12. Serum Institute of India Pvt. Ltd.
  • 18.13. Sinopharm Group Co. Ltd.
  • 18.14. Sinovac Biotech Ltd.

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Pediatric Preventable Vaccine Market, Years Considered for the Study
  • FIGURE 2. Global Pediatric Preventable Vaccine Market, Research Design
  • FIGURE 3. Global Pediatric Preventable Vaccine Market, Research Framework
  • FIGURE 4. Global Pediatric Preventable Vaccine Market, Data Triangulation
  • FIGURE 5. Global Pediatric Preventable Vaccine Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Pediatric Preventable Vaccine Market Size, by Age Group, 2025 vs 2032 (%)
  • FIGURE 9. Global Pediatric Preventable Vaccine Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Pediatric Preventable Vaccine Market Size, by Technology, 2025 vs 2032 (%)
  • FIGURE 11. Global Pediatric Preventable Vaccine Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 13. Global Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Pediatric Preventable Vaccine Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 15. Global Pediatric Preventable Vaccine Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Pediatric Preventable Vaccine Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 19. Global Pediatric Preventable Vaccine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Pediatric Preventable Vaccine Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Pediatric Preventable Vaccine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Pediatric Preventable Vaccine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Pediatric Preventable Vaccine Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Pediatric Preventable Vaccine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Pediatric Preventable Vaccine Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Pediatric Preventable Vaccine Market Segmentation & Coverage
  • TABLE 2. Global Pediatric Preventable Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 4. Global Diphtheria Tetanus Pertussis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Diphtheria Tetanus Pertussis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Diphtheria Tetanus Pertussis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Haemophilus Influenzae Type B Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Haemophilus Influenzae Type B Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Haemophilus Influenzae Type B Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Hepatitis B Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Hepatitis B Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Hepatitis B Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Measles Mumps Rubella Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Measles Mumps Rubella Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Measles Mumps Rubella Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Pneumococcal Conjugate Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Pneumococcal Conjugate Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Pneumococcal Conjugate Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Polio Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Polio Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Polio Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Varicella Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Varicella Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Varicella Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 26. Global Adolescence Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Adolescence Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Adolescence Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Infant Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Infant Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Infant Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Neonate Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Neonate Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Neonate Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Preschool Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Preschool Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Preschool Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global School Age Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global School Age Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global School Age Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Toddler Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Toddler Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Toddler Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 45. Global Conjugate Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Conjugate Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Conjugate Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Subunit Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Subunit Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Subunit Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Toxoid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Toxoid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Toxoid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 61. Global Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Nasal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Nasal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Nasal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 71. Global Multi Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Multi Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Multi Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Single Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Single Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Single Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 78. Global Private Sector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Private Sector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Private Sector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Public Sector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global Public Sector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global Public Sector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global Government Programs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Global Government Programs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. Global Government Programs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 93. Global International Aid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Global International Aid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. Global International Aid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. Global Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 97. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 99. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 100. Global Community Health Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Global Community Health Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 102. Global Community Health Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 103. Global Private Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Global Private Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 105. Global Private Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 106. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 107. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 108. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 109. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 110. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 111. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 112. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 113. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 114. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 115. Global Outreach Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 116. Global Outreach Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 117. Global Outreach Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 118. Global Community Camps Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 119. Global Community Camps Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 120. Global Community Camps Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 121. Global Mobile Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 122. Global Mobile Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. Global Mobile Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 124. Global Pediatric Preventable Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 125. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 126. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 127. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 128. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 129. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 130. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 131. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 132. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 133. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 134. Asia-Pacific Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 135. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 136. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 137. Asia-Pacific Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 138. North America Pediatric Preventable Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 139. North America Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 140. North America Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 141. North America Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 142. North America Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 143. North America Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 144. North America Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 145. North America Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 146. North America Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 147. North America Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 148. North America Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 149. North America Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 150. North America Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 151. Latin America Pediatric Preventable Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 152. Latin America Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 153. Latin America Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 154. Latin America Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 155. Latin America Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 156. Latin America Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 157. Latin America Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 158. Latin America Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 159. Latin America Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 160. Latin America Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 161. Latin America Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 162. Latin America Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 163. Latin America Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 164. Europe Pediatric Preventable Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 165. Europe Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 166. Europe Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 167. Europe Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 168. Europe Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 169. Europe Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 170. Europe Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 171. Europe Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 172. Europe Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 173. Europe Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 174. Europe Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 175. Europe Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 176. Europe Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 177. Middle East Pediatric Preventable Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 178. Middle East Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 179. Middle East Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 180. Middle East Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 181. Middle East Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 182. Middle East Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 183. Middle East Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 184. Middle East Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 185. Middle East Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 186. Middle East Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 187. Middle East Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 188. Middle East Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 189. Middle East Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 190. Africa Pediatric Preventable Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 191. Africa Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 192. Africa Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 193. Africa Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 194. Africa Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 195. Africa Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 196. Africa Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 197. Africa Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 198. Africa Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 199. Africa Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 200. Africa Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 201. Africa Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 202. Africa Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 203. Global Pediatric Preventable Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 204. ASEAN Pediatric Preventable Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 205. ASEAN Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 206. ASEAN Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 207. ASEAN Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 208. ASEAN Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 209. ASEAN Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 210. ASEAN Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 211. ASEAN Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 212. ASEAN Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 213. ASEAN Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 214. ASEAN Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 215. ASEAN Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 216. ASEAN Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 217. GCC Pediatric Preventable Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 218. GCC Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 219. GCC Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 220. GCC Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 221. GCC Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 222. GCC Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 223. GCC Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 224. GCC Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 225. GCC Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 226. GCC Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 227. GCC Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 228. GCC Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 229. GCC Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 230. European Union Pediatric Preventable Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 231. European Union Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 232. European Union Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 233. European Union Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 234. European Union Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 235. European Union Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 236. European Union Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 237. European Union Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 238. European Union Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 239. European Union Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 240. European Union Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 241. European Union Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 242. European Union Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 243. BRICS Pediatric Preventable Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 244. BRICS Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 245. BRICS Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 246. BRICS Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 247. BRICS Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 248. BRICS Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 249. BRICS Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 250. BRICS Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 251. BRICS Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 252. BRICS Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 253. BRICS Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 254. BRICS Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 255. BRICS Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 256. G7 Pediatric Preventable Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 257. G7 Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 258. G7 Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 259. G7 Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 260. G7 Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 261. G7 Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 262. G7 Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 263. G7 Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 264. G7 Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 265. G7 Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 266. G7 Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 267. G7 Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 268. G7 Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 269. NATO Pediatric Preventable Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 270. NATO Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 271. NATO Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 272. NATO Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 273. NATO Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 274. NATO Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 275. NATO Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 276. NATO Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 277. NATO Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 278. NATO Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 279. NATO Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 280. NATO Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 281. NATO Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 282. Global Pediatric Preventable Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 283. United States Pediatric Preventable Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 284. United States Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 285. United States Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 286. United States Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 287. United States Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 288. United States Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 289. United States Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 290. United States Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 291. United States Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 292. United States Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 293. United States Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 294. United States Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 295. United States Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 296. Canada Pediatric Preventable Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 297. Canada Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 298. Canada Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 299. Canada Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 300. Canada Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 301. Canada Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 302. Canada Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 303. Canada Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 304. Canada Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 305. Canada Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 306. Canada Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 307. Canada Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 308. Canada Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 309. Mexico Pediatric Preventable Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 310. Mexico Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 311. Mexico Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 312. Mexico Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 313. Mexico Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 314. Mexico Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 315. Mexico Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 316. Mexico Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 317. Mexico Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 318. Mexico Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 319. Mexico Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 320. Mexico Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 321. Mexico Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 322. Brazil Pediatric Preventable Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 323. Brazil Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 324. Brazil Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 325. Brazil Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 326. Brazil Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 327. Brazil Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 328. Brazil Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 329. Brazil Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 330. Brazil Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 331. Brazil Pediatric Preventable Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 332. Brazil Pediatric Preventable Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 333. Brazil Pediatric Preventable Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 334. Brazil Pediatric Preventable Vaccine Market Size, by Outreach Centers, 2017-2032 (USD Million)
  • TABLE 335. United Kingdom Pediatric Preventable Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 336. United Kingdom Pediatric Preventable Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 337. United Kingdom Pediatric Preventable Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 338. United Kingdom Pediatric Preventable Vaccine Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 339. United Kingdom Pediatric Preventable Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 340. United Kingdom Pediatric Preventable Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 341. United Kingdom Pediatric Preventable Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 342. United Kingdom Pediatric Preventable Vaccine Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 343. United Kingdom Pediatric Preventable Vaccine Market Size, by Public Sector, 2017-2032 (USD Million)
  • TABLE 344. Uni